TY  - RPRT
TI  - Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.
AU  - Janet R Walczak
AU  - Michael A Carducci
AU  - Eastern Cooperative Oncology Group E1899
PY  - 2003
DO  - 10.1016/j.urology.2003.09.006
UR  - https://pubmed.ncbi.nlm.nih.gov/14747052/
ID  - 14747052
ER  -